Avian influenza other diagnostic studies

Revision as of 01:00, 24 April 2015 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Avian influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Avian influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Avian influenza other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Avian influenza other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Avian influenza other diagnostic studies

CDC on Avian influenza other diagnostic studies

Avian influenza other diagnostic studies in the news

Blogs on Avian influenza other diagnostic studies

Directions to Hospitals Treating Avian influenza

Risk calculators and risk factors for Avian influenza other diagnostic studies

For more information about seasonal human influenza virus that is not associated with animal exposure, see Influenza

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Other diagnostic test for influenza include molecular assays, such as RT-PCR. New technologies being pursued include those that examine influenza viruses at the molecular level. By examining the genetic makeup of influenza viruses, such tests could identify both the virus type and subtype simultaneously.

Other Diagnostic Studies

Molecular Assays Adapted from CDC [1]

  • Tests for influenza include:
  • Molecular assays
  • Rapid influenza diagnostic tests
  • Viral culture
  • Serology
  • Molecular assays for influenza are increasingly being used in clinical settings.
  • Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and other molecular assays can identify the presence of influenza viral RNA in respiratory specimens.
  • RT-PCR is particularly useful to identify influenza virus infection as a cause of respiratory outbreaks in institutions, such as nursing homes, chronic care facilities, and hospitals.
  • Some molecular assays are able to detect and discriminate between infections with influenza A and B viruses; other tests can identify specific influenza A virus subtypes.
  • These assays can yield results in 3-8 hours.
  • Notably, the detection of influenza viral RNA by these assays does not always indicate detection of viable virus or on-going influenza viral replication.
  • It is important to note that not all assays have been cleared by the FDA for diagnostic use.
Advantages Disadvantages
  • Molecular assays are more sensitive and specific for detecting influenza viruses than other influenza tests (e.g., rapid influenza diagnostic tests, immunofluorescence, and viral culture)
  • The likelihood of a false positive or false negative result is low and therefore, the interpretation of the result is less impacted by the level of influenza activity in the community
  • Some, but not all molecular assays can distinguish between specific influenza A virus subtypes
  • Results of RT-PCR and other molecular assays may not be available in a clinically relevant time frame to inform clinical management decisions.
  • RT-PCR and other molecular assays are generally not available for outpatient or emergency room settings.
  • Respiratory specimens may need to be sent to a state public health laboratory or commercial laboratory for RT-PCR. Therefore, although the test can yield results in 3-8 hours, the actual time to receive results may be substantially longer.
  • Most molecular assays are not approved to test lower respiratory tract specimens.
  • RT-PCR and other molecular assays are generally more expensive.
  • They may not specifically identify all of the subtypes of influenza A virus.
  • Depending on the test, a negative result for one influenza A virus subtype may not preclude infection with another influenza A virus subtype.
  • Some tests are not FDA-cleared and an evaluation has not been performed to assess the accuracy of all available RT-PCR and molecular assays.

References

  1. "CDC Guidance for Clinicians on the Use of RT-PCR and Other Molecular Assays for Diagnosis of Influenza Virus Infection".